Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2870 vs chemotherapy in previously treated nonsquamous EGFR-mutant NSCLC
jRCT2031240108Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of sacituzumab tirumotecan in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merck & Co. Primary endpoints: Progression-Free Survival in EGFR-mutated NSCLC and Overall Survival in EGFR-mutated NSCLC. Started Jul 2024; status: active, not recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031240108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240108.